Dr. Andrés Finzi from the Université de Montréal and Dr. Renée Bazin from Héma-Québec and their teams recently describe a novel high-throughput method to track levels of antibodies made against SARS-CoV-2 spike protein in the plasma of donors that recovered from COVID-19 in a recent issue of Transfusion.
Dr. Andrés Finzi, from the Université de Montréal, Dr. Renée Bazin from Héma-Québec, along with collaborators from Western University, are highlighting the importance of antibodies made early on in the infection in SARS-CoV-2 neutralization.
Researchers find cellular immune response to SARS-CoV-2 lasts at least eight months, even after antibodies levels decreased
Researchers from Université de Montréal, Dr Daniel Kaufmann and Dr Andres Finzi, in collaboration with researchers from New York University, are confirming the presence of a long-lasting immune response to the novel coronavirus SARS-CoV-2, in a pre-print publication.
Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile
Researchers at the University of Toronto, published in the Journal of Immunology, shed light on what is happening in the body may help to explain why patients with SARS-CoV-2 have more severe inflammation and lung tissue damage than patients suffering from regular seasonal influenza virus.
Investigators at the Université de Montréal, published in mBio, has investigated the duration of antibodies against SARS-CoV-2 in people who were recovering from COVID-19. This has important implications for the use of plasma as a potential treatment for COVID-19.
Researchers find antibodies capable of blocking infection in recovered COVID-19 patients, but they may not last long
Researchers from Université de Montréal and Héma Québec and collaborators across Canada are reporting that patients recovered from severe COVID tend to have stronger antibody responses.